564 related articles for article (PubMed ID: 33710721)
1. Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis.
Giugliano D; Longo M; Caruso P; Maiorino MI; Bellastella G; Esposito K
Diabetes Obes Metab; 2021 Jul; 23(7):1672-1676. PubMed ID: 33710721
[TBL] [Abstract][Full Text] [Related]
2. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
Rao S
Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
[TBL] [Abstract][Full Text] [Related]
3. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs.
Giugliano D; Longo M; Scappaticcio L; Bellastella G; Maiorino MI; Esposito K
Cardiovasc Diabetol; 2021 Dec; 20(1):236. PubMed ID: 34915880
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.
Duan XY; Liu SY; Yin DG
Medicine (Baltimore); 2021 Jul; 100(30):e26431. PubMed ID: 34397684
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis.
Nguyen BN; Nguyen L; Mital S; Bugden S; Nguyen HV
Diabetes Obes Metab; 2023 Jun; 25(6):1614-1623. PubMed ID: 36751968
[TBL] [Abstract][Full Text] [Related]
6. Effects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes.
Chilton RJ
Diabetes Obes Metab; 2020 Jan; 22(1):16-29. PubMed ID: 31407866
[TBL] [Abstract][Full Text] [Related]
7. Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials.
Giugliano D; De Nicola L; Maiorino MI; Bellastella G; Esposito K
Diabetes Obes Metab; 2019 Aug; 21(8):1790-1800. PubMed ID: 30969018
[TBL] [Abstract][Full Text] [Related]
8. Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease.
Solomon J; Festa MC; Chatzizisis YS; Samanta R; Suri RS; Mavrakanas TA
Pharmacol Ther; 2023 Feb; 242():108330. PubMed ID: 36513134
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.
Kanters S; Wilkinson L; Vrazic H; Sharma R; Lopes S; Popoff E; Druyts E
BMJ Open; 2019 Jul; 9(7):e023458. PubMed ID: 31340953
[TBL] [Abstract][Full Text] [Related]
10. Exploring the comparative cardiovascular death benefits of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoring.
Ghosal S; Sinha B
Front Endocrinol (Lausanne); 2023; 14():1168755. PubMed ID: 37469980
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis.
Hussein H; Zaccardi F; Khunti K; Davies MJ; Patsko E; Dhalwani NN; Kloecker DE; Ioannidou E; Gray LJ
Diabetes Obes Metab; 2020 Jul; 22(7):1035-1046. PubMed ID: 32077218
[TBL] [Abstract][Full Text] [Related]
12. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials.
Singh AK; Singh R
Diabetes Metab Syndr; 2020; 14(3):181-187. PubMed ID: 32142999
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Kosiborod M; Lam CSP; Kohsaka S; Kim DJ; Karasik A; Shaw J; Tangri N; Goh SY; Thuresson M; Chen H; Surmont F; Hammar N; Fenici P;
J Am Coll Cardiol; 2018 Jun; 71(23):2628-2639. PubMed ID: 29540325
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: A trial-level meta-analysis including 51 713 individuals.
Huang CY; Lee JK
Diabetes Obes Metab; 2020 Dec; 22(12):2348-2355. PubMed ID: 32744411
[TBL] [Abstract][Full Text] [Related]
15. Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.
Hinton W; Feher MD; Munro N; Joy M; de Lusignan S
Cardiovasc Diabetol; 2021 Jun; 20(1):130. PubMed ID: 34183018
[TBL] [Abstract][Full Text] [Related]
16. Healthcare resource utilization after initiation of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors or other glucose-lowering drugs in Japanese patients with type 2 diabetes.
Kohsaka S; Takeda M; Kidani Y; Yajima T
Diabetes Obes Metab; 2021 Apr; 23 Suppl 2():28-39. PubMed ID: 33835640
[TBL] [Abstract][Full Text] [Related]
17. [Outcome studies on SGLT-2 inhibitors].
Seufert J; Laubner K
Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
[TBL] [Abstract][Full Text] [Related]
18. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
Butler J; Handelsman Y; Bakris G; Verma S
Eur J Heart Fail; 2020 Apr; 22(4):604-617. PubMed ID: 31926059
[TBL] [Abstract][Full Text] [Related]
19. Sodium-Glucose Cotransport Protein 2 Inhibitors in Patients With Type 2 Diabetes and Acute Kidney Disease.
Pan HC; Chen JY; Chen HY; Yeh FY; Huang TT; Sun CY; Wang SI; Wei JC; Wu VC
JAMA Netw Open; 2024 Jan; 7(1):e2350050. PubMed ID: 38170522
[TBL] [Abstract][Full Text] [Related]
20. Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data.
Patel K; Carbone A
Ann Pharmacother; 2019 Dec; 53(12):1227-1237. PubMed ID: 31226886
[No Abstract] [Full Text] [Related]
[Next] [New Search]
